The alert describes 3 issues:
1. Some Emerade pens have failed to activate, which could lead to an injection of adrenaline not being administered in cases of anaphylaxis – the alert provides advice to patients regarding administration.
2. To support adequate supply of adrenaline auto-injectors in the UK, an extension by 4 months of the use-by dates has been approved for specific batches of Jext 150 and 300 microgram adrenaline auto-injectors and specific batches of EpiPen 300 microgram adrenaline auto-injectors.
3. Patients should continue to follow existing advice to carry 2 in-date pens with them at all times.